End-of-life care preferences in penile cancer patients: Shifting patterns and disparities over two decades.

M Mahnoor Sukaina (4Karachi Medical and Dental College, Karachi, Pakistan) R Rutvi Chahal (Government Medical College and Hospital, Chandigarh, India) A Atulya Aman Khosla Y Yagnapriya Ammakola (2Corewell Health William Beaumont University Hospital, Royal Oak, United States) M Manas Pustake (2Texas Tech University El Paso, El Paso, United States) C Chandra Kakarala (1University of Kentucky, Lexington, United States) N Nitya Batra (1Mayo Clinic, Hematology & Oncology, Jacksonville, United States) R Rahul Mishra M Madhan Srinivasan Kumar (Saint Vincent Hospital, Worcester, MA) A Aruni Ghose (Immuno-Oncology Clinical Network, Liverpool, United Kingdom) J Jayasree Krishnan (Roswell Park Comprehensive Cancer Center, Buffalo, NY) M Mohammad Arfat Ganiyani (6Miami Cancer Institute, Miami, United States) R Rohit Singh R Rohan Garje (3Miami Cancer Institute, Baptist Health South Florida, Miami, United States) K Karan Jatwani (7George Washington University School of Medicine, Washington DC, United States)

Abstract

5 Background: Penile cancer (PC) is often diagnosed late, which leads to advanced disease. Studies have reported that less than 18% of individuals with metastatic PC receive any kind of palliative therapy. Place of Death (PoD) is a crucial determinant of patient and caregiver preferences and the cost of caregiving at the end of life (EOL). We aimed to evaluate the trends in PoD for patients with PC in the U.S. from 2003 to 2023 based on the CDC WONDER (Wide-ranging Online Data for Epidemiologic Research) database. Methods: We analyzed data from January 01, 2003, to December 31, 2023. The data for deaths due to PC were pooled using the International Classification of Diseases-10th Revision code as C60 for malignant neoplasm of the penis. The inclusion criteria included patients aged > 25 years. PoD is defined as deaths at home and hospice (H&H) versus medical facilities. Average annual percentage change (AAPC) was calculated using the Joinpoint Regression Program, version 5.0.2. Results: The analysis demonstrated a total of n = 6,074 deaths from PC. A total of 52.1% of deaths, n = 3,167, were reported at H&H. The trend analysis demonstrates an exponential rise in H&H utilization from 34.4% in 2003 to 57.5% in 2023, AAPC [5.4284, CI (4.7-6.10, p < 0.000001]. A significant increase in the utilization of H&H is notable in both African Americans (AA), AAPC [2.8514, CI (1.0-4.7), p = 0.004], and the White population, AAPC [5.3497, CI (4.6-6.0); p < 0.000001]. However, a racial disparity is also noted, with 45.4% in AA, while the White population is at 52.5% deaths in H&H-based care. PC mortality in medical facilities has a 29.7% decline from 2003 to 2023. On age stratification, there was a significant increase in utilizing H&H as PoD for the 45-64 years cohort AAPC [4.29, CI (3.2, 5.2), p < 0.000001], similarly, with the older age group 65+ cohorts AAPC [6.26, CI (5.4, 7.0), p < 0.000001]. In contrast, the younger cohort deduced no significant trend AAPC [2.92, CI (-1.5, 7.6), p = 0.14]. Conclusions: This is the first study to our knowledge providing valuable insights into the evolving PoD preferences among PC patients in the U.S.The age-related trends underscore the importance of tailoring end-of-life care strategies to specific age cohorts. The findings emphasize the importance of policies promoting and supporting H&H care for PC patients. Targeted efforts are warranted to address notable disparities in PoD preferences among racial and age groups.

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 5-5
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (15)

M

Mahnoor Sukaina

4Karachi Medical and Dental College, Karachi, Pakistan

R

Rutvi Chahal

Government Medical College and Hospital, Chandigarh, India

A

Atulya Aman Khosla

Y

Yagnapriya Ammakola

2Corewell Health William Beaumont University Hospital, Royal Oak, United States

M

Manas Pustake

2Texas Tech University El Paso, El Paso, United States

C

Chandra Kakarala

1University of Kentucky, Lexington, United States

N

Nitya Batra

1Mayo Clinic, Hematology & Oncology, Jacksonville, United States

R

Rahul Mishra

M

Madhan Srinivasan Kumar

Saint Vincent Hospital, Worcester, MA

A

Aruni Ghose

Immuno-Oncology Clinical Network, Liverpool, United Kingdom

J

Jayasree Krishnan

Roswell Park Comprehensive Cancer Center, Buffalo, NY

M

Mohammad Arfat Ganiyani

6Miami Cancer Institute, Miami, United States

R

Rohit Singh

R

Rohan Garje

3Miami Cancer Institute, Baptist Health South Florida, Miami, United States

K

Karan Jatwani

7George Washington University School of Medicine, Washington DC, United States